Localization of recognition site between transforming growth factor-β1 (TGF-β1) and TGFβ receptor type II: Possible implications in breast cancer

Medical Hypotheses

Volumn 62, Issue 5, 2004, Pages 727-732

  Ivanovic V ^a   Demajo, M ^a   Todorovic Rakovic N ^b   Nikolic Vukosavljevic D ^b   Neskovic Konstantinovic Z ^b   Krtolica, K ^a   Veljkovic V ^a   Prljic J ^a   Dimitrijevic B ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; BREAST CANCER; CANCER GROWTH; COLON CANCER; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; FOURIER TRANSFORMATION; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STOMACH CANCER; TUMOR PROMOTION;

EID: 2142696747     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.11.027     Document Type: Article

References (35)

1. 1 associates with disease progression in human breast cancer. Cancer Res 1992;52:6949-52.
2. 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222:155-62.
3. 1) in patients with advanced breast cancer:association with disease progression. Eur J Cancer 2003;39:454-61.
4. Lawrence DA. Transforming growth factor-β: a general review. Eur Cytokine Netw 1996;7:363-74.
5. 1 in ductal carcinoma in situ and invasive carcinoma of the breast. Eur J Cancer 1992;28:641-4.
6. 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993;143:381-9.
7. 1 and second primary breast cancer in a chemoprevention trial. Eur J Cancer 1998;34:999-1003.
8. 1) in human plasma - a pilot study on breast cancer patients. Jugoslav Med Biochem 2001;19:81-7.
9. 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996;110:375-82.
10. 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 1996;74:753-8.
11. 1 in patients with invasive prostate cancer. Nat Med 1995;1:282-4.
12. 1 as a prognostic biomarker of prostate carcinoma. Arch Oncol 1998;6:159-62.
13. 2 in serum and urine from patients with bladder carcinoma. J Urol 1996;156:953-7.
14. Reiss M, Barcellos-Hoff MH. Transforming growth factor-β in breast cancer:A working hypothesis. Breast Cancer Res Treat 1997;45:81-95.
15. Akhurst RJ, Balman A. Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol 1999;187:82-90.
16. Lin HY, Moustakas A. TGF-β receptors:structure and function. Cell Mol Biol 1994;40:337-49.
17. Yingling JM, Wang XF, Bassing CH. Signaling by the transforming growth factor-β receptors. Biochim Biophys Acta 1995;1242:115-36.
18. 1 in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997;31:61-70.
19. Myeroff LL, Parsons R, Kim SJ, et al. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-7.
20. Wang J, Sun L, Myeroff L, et al. Demonstration that mutations of the type II transforming growth factor β receptor inactivates its tumor supressor activity in replication error-positive colon carcinoma cells. J Biol Chem 1995;270:22044-9.
21. Takenoshita S, Mogi A, Tani M, et al. Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-β receptor type II gene in sporadic human breast cancers. Oncol Rep 1998;5:367-71.
22. Tomita S, Deguchi S, Miyguni T, Muto Y, Tamamoto T, Toda T. Analyses of microsatellite instability and the transforming growth factor β receptor type II gene mutations in sporadic breast cancer and their correlation with clinicopathological features. Breast Cancer Res Treat 1999;53:33-9.
23. Veljkovic V, Cosic I. A novel method of protein analysis for prediction of biological function: application to tumor toxins. Cancer Biochem Biophys 1987;9:139-48.
24. Cosic I, Nesic D. Prediction of "hot spots" in SV40 enhancer and relation with experimental data. Eur J Biochem 1988;170:247-52.
25. Cosic I, Pavlovic M, Vojisavljevic V. Prediction of "hot spots" in interleukin-2 based on informational spectrum characteristics of growth regulating factor. Biochemie 1989;71:333-9.
26. Krsmanovic B, Cosic I, Biquard J, Hearn M. Investigation into crossreactivity of rabbit antibodies raised against nonhomologous pairs of synthetic peptides derived from HIV-1gp120 proteins. J Peptide Res 1998;52:410-8.
27. Veljkovic V. The dependence of the Fermi energy on the atomic number. Phys Lett 1973;45A:41-2.
28. Veljkovic V, Cosic I, Dimitrijevic B, Lalovic D. Is it possible to analyze DNA and protein sequence by the method of digital signal processing? IEEE Biomed Trans 1985;32:337-41.
29. Cosic I, Nesic D, Pavlovic M, Williams R. Enhancer binding proteins predicted by informational spectrum method. Biochem Biophys Res Commun 1986;141:831-8.
30. Hoefer M, Anderer FA. Anti-(transforming growth factor β) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol Immunother 1995;41:302-8.
31. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/2-HS glycoprotein is a transforming growth factor β receptor type II mimic and cytokine antagonist. J Biol Chem 1996;271:12755-61.
32. Pepin MC, Beauchemin M, Plamodon J, O'Connor-McCourt MD. Scanning-deletion analysis of the extracellular domain of the TGF-receptor type II. Biochem Biophys Res Commun 1996;220:289-93.
33. Boesen CC, Radaev S, Motyka SA, Patamawenu A, Sun PD. The 1.1 Å crystal structure of human TGF-β type II receptor ligand binding domain. Structure (Camb) 2002;10:913-9.
34. 1 in blood: a complex problem. Cytokine Growth Factor Rev 2000;11:133-45.
35. 1) and TGFβ receptor type II as diagnostic biomarkers in breast cancer. SMn Patent Application No. 584-03, 23 August, 2003.